IDE849 (SHR-4849) DLL3 TOP1 ADC UPDATED PHASE 1 RESULTS AT ESMO 2026 DEMONSTRATES PROMISING ANTI-TUMOR ACTIVITY AND PRELIMINARY OVERALL SURVIVAL RESULTS IN RELAPSED SMALL CELL LUNG CANCER AND NEUROENDOCRINE CARCINOMAS

Reuters · 2d ago

Please log in to view news